Medical Information
United States

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

Información selecta para pacientes y cuidadores que se encuentra disponible en Español.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

BENEFIX®Clinical Pharmacology (Coagulation Factor IX (Recombinant))


12.1 Mechanism of Action

BeneFIX temporarily replaces the missing clotting factor IX that is needed for effective hemostasis.

12.2 Pharmacodynamics

The activated partial thromboplastin time (aPTT) is prolonged in people with hemophilia B. Treatment with factor IX concentrate may normalize the aPTT by temporarily replacing the factor IX. The administration of BeneFIX increases plasma levels of factor IX, and can temporarily correct the coagulation defect in these patients.

12.3 Pharmacokinetics

In a randomized, cross-over pharmacokinetic study, BeneFIX reconstituted in 0.234% sodium chloride diluent was shown to be pharmacokinetically equivalent to the previously marketed BeneFIX (reconstituted with Sterile Water for Injection) in 24 previously treated patients (≥12 years) at a dose of 75 IU/kg. In addition, pharmacokinetic parameters were followed up in 23 previously treated patients after repeated administration of BeneFIX for six months and found to be unchanged compared with those obtained at the initial evaluation. A summary of pharmacokinetic data are presented in Table 4:

Table 4: Pharmacokinetic Parameter Estimates for BeneFIX (75 IU/kg) at Baseline and Month 6 in Previously Treated Patients with Hemophilia B
N = 24
Mean ± SD
Month 6
N = 23
Mean ± SD
Abbreviations: AUC = area under the plasma concentration-time curve from time zero to infinity; Cmax = peak concentration; t1/2 = plasma elimination half-life; CL = clearance; SD = standard deviation.
Cmax (IU/dL)54.5 ± 15.057.3 ± 13.2
AUC (IU∙hr/dL)940 ± 237923 ± 205
t1/2 (hr) 22.4 ± 5.323.8 ± 6.5
CL (mL/hr/kg)8.47 ± 2.128.54 ± 2.04
(IU/dL per IU/kg)
0.73 ± 0.200.76 ± 0.18

Pediatric Patients (<12 years)

A population pharmacokinetic model was developed using data collected in patients aged 7 months to 60 years who received single doses of BeneFIX ranging from 50 to 75 IU/kg. The parameters estimated using the final 2-compartment model are shown in Table 5. Infants and children had higher clearance, larger volume of distribution, shorter half-life and lower recovery than adolescents and adults.

Table 5: Mean ± SD Pharmacokinetic Parameters Derived from Population Pharmacokinetic Analysis
Age GroupInfants (<2 years)ChildrenAdolescents and Adults (≥12 years)
2 to <6 yr6 to <12 yr
Abbreviations: SD = standard deviation; Vss = volume of distribution at steady-state
Number of subjects716143
Clearance (mL/h/kg)13.1 ± 2.113.1 ± 2.815.58.4 ± 2.4
Vss (mL/kg)252 ± 35257 ± 25303229 ± 57
Half-life (h)15.6 ± 1.216.7 ± 1.916.323.1 ± 4.4
Recovery (IU/dL per IU/kg)0.61 ± 0.100.60 ± 0.080.470.72 ± 0.19

Data from 57 PUP subjects who underwent repeat recovery testing for up to 60 months demonstrated that the average recovery was consistent over time, as shown in Figure 1.

Figure 1

Figure 1. Average Recovery over Time

Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event